A5035173867- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Treatments and Mutations
- Statistical Methods in Clinical Trials
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- COVID-19 and healthcare impacts
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lung Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Multiple and Secondary Primary Cancers
- Biomedical Ethics and Regulation
- Hepatocellular Carcinoma Treatment and Prognosis
- Ovarian cancer diagnosis and treatment
- Vehicle Noise and Vibration Control
- Soil Mechanics and Vehicle Dynamics
- Cancer survivorship and care
- Ethics in Clinical Research
- CAR-T cell therapy research
- Renal cell carcinoma treatment
- Neutropenia and Cancer Infections
- Metastasis and carcinoma case studies
- Endometrial and Cervical Cancer Treatments
A. O. Ordine Mauriziano di Torino
2021-2024
University of Turin
2021-2024
Policlinico Umberto I
2021
COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by pandemic. This multicenter Italian study aimed to evaluate whether outbreak had an impact on access diagnosis and treatment of LC pts compared with pre-pandemic time.Consecutive newly diagnosed referred 25 Oncology Departments between December 2020 were included. Access rate temporal intervals date symptoms onset diagnostic therapeutic...
Background: The Gustave Roussy Immune (GRIm)-Score takes into account neutrophil-to-lymphocyte ratio (NLR), serum albumin concentration and lactate dehydrogenase (LDH) its prognostic value has been investigated in patients treated with immune check-point inhibitors (ICIs). To further assess the predictive of baseline GRIm-Score (GRImT0) advanced non-small cell lung cancer (aNSCLC) patients, we separately two cohorts first-line pembrolizumab or chemotherapy. We also whether at 45 days since...
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients various malignancies including non-small cell lung cancer (NSCLC). However, it unclear whether baseline BMI may influence outcomes first-line chemoimmunotherapy combinations. Methods In this international multicenter study, we evaluated the association between BMI, progression-free survival (PFS) and overall (OS) a cohort of stage...
To assess time trends in the inclusion of health-related quality life (QoL) among study endpoints and reporting QoL results publications, randomised phase III oncology trials published between 2017 2021 were compared with previous 5 years. All issues 2012 by 11 major journals handsearched for primary publications adult patients solid tumours. Trials 2017-2021 2012-2016 three endpoints: (1) proportion including out all eligible publications; (2) presenting those (3) data publications. 388 446...
BackgroundGeneralizability of registrative clinical trials to real-world practice is influenced by comparability patients in the two settings. We compared characteristics cancer with Italy.MethodsData on age, sex and performance status (PS) were derived from web-based monitoring registries developed Italian Medicines Agency (AIFA) corresponding reported European Public Assessment Reports (EPAR) (EMA). Weighted means calculated differences described. Multivariate analysis was performed using...
Despite the interest from scientific community and regulatory agencies, limited data are available on association between health-related quality-of-life (QoL) results, outcome of efficacy drug approvals.
Background: There is poor evidence about sensitivity to chemotherapy according microsatellite instability (MSI)/mismatch repair (MMR) status in endometrial cancer (EC). 
 Methodology: The RAME study a retrospective analysis aiming assess response MSI-high (h) /deficient (d) MMR and MSI- low (l)/proficient (p)MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease progression-free (PFS) overall (OS) advanced/recurrent disease.
...
Background: There is poor evidence regarding sensitivity to chemotherapy in endometrial cancer (EC) based on microsatellite instability (MSI)/mismatch repair (MMR) status. Methodology: The RAME study a retrospective analysis aiming assess response MSI-high (h)/deficient (d) MMR and MSI-low (l)/proficient (p) EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease progression-free (PFS) overall (OS) advanced/recurrent disease. Results: A total of...
Background: Tyrosine kinase inhibitors (TKIs) show variable efficacy in epidermal growth factor receptor mutation-positive (EGFR+) NSCLC patients, even patients harbouring the same mutation. Co-alterations may predict different outcomes to TKIs. Methods: We retrospectively analysed all consecutive EGFR+ advanced treated with first-line TKIs at our Institutions. NGS a 22 genes clinical panel was performed on diagnostic specimens. PD-L1 expression also evaluated. Results: Of 106 specimens, 59...
Abstract In the past years, treatment options for advanced hepatocellular carcinoma (HCC) have thriven. Although globally recognised, patient‐reported outcomes (PROs) are often underused and quality of life (QoL) results underreported in many phase III trials. We performed a systematic review to describe prevalence QoL inclusion heterogeneity reporting published trials systemic HCC. Twenty‐one publications were identified: 12 (57.1%) first line setting, eight (38.1%) second only one (4.7%)...
Nivolumab is approved and reimbursed by Italian Drug Agency (AIFA) in several tumors, including non-small cell lung cancer, head & neck cancer renal cancer.In May 2018, the original schedule (3 mg/kg every 2 weeks) -used pivotal clinical trials demonstrating treatment efficacy -was replaced a flat dose (240 mg weeks).Aim of this study was to identify most cost-effective dosing strategy nivolumab real-world setting.The primary endpoint analysis difference costs between real scenario based on...
6569 Background: Long-term cancer survivors (LTS) patients (pts) treated with immunotherapy (IT) represent a relatively new population whose characteristics, such as long-term toxicities, quality of life (QoL), and financial need to be elucidated in real-world setting. The aim this study is evaluate toxicities free disease progression IT. Methods: This cross-sectional, multicentric study, involving ten Italian centres. Pts should have started IT (as monotherapy or combination, either...